



## PRESS RELEASE

August 25, 2023

# Analyst interview with Ziccum CEO on significant milestones achieved

**With two paid Evaluation agreements signed with world-leading mRNA partners, after having proven the LaminarPace technology for mRNA/LNP treatment, Q2 2023 was the most successful in Ziccum's history. CEO Ann Gidner describes the company's achievements and road ahead in the first of two CEO interviews.**

Watch Ziccum CEO Ann Gidner in the first of two interviews with Eucaps analyst Jonathan Furelid [HERE](#)

Or visit Ziccum's company page on Eucaps [HERE](#).

**For more information about Ziccum, please contact:**

---

Ann Gidner,  
CEO Ziccum  
Mail: [gidner@ziccum.com](mailto:gidner@ziccum.com)  
Mobile: +46 722140141

Fredrik Sjövall,  
Chairman of the Board, Ziccum AB  
Mail: [sjovall@ziccum.com](mailto:sjovall@ziccum.com)  
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is Erik Penser Bank AB  
Follow us on <https://eucaps.com/ziccum>

## About Ziccum

---

Ziccum is developing LaminarPace™, a unique ambient drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

---

[Analyst interview with Ziccum CEO on significant milestones achieved](#)